China's agriculture ministry approved Zhejiang Hisun Pharmaceutical's (SHA:600267) veterinary drug approval for its nystatin ointment and toltrazuril suspension, according to a Friday filing with the Shanghai bourse.
Shares rose 1% during afternoon trading on Monday.
Nystatin ointment is used for otitis externa or outer ear infection in dogs and cats caused by bacteria, fungi, and ear mites, the filing said.
Toltrazuril is indicated for the prevention of coccidiosis or a protozoan infection in chicken causing diarrhea.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments